Corporate debt recently passed the $1 trillion mark in a continuing sign of global financial displacement.Marketsread more
"Federal debt, which is already high by historical standards, is on an unsustainable course," CBO director Phillip Swagel said in the report.Politicsread more
Target CEO Brian Cornell still thinks the U.S. consumer is strong and spending. Target's latest quarterly results showed the big-box retailer is benefiting from that.Retailread more
"If you look at the market over the past week, stocks don't need any help. They are roaring ahead, without the Fed doing anything," says the longtime market strategist.Marketsread more
Stocks rose on Wednesday as strong quarterly results from retailers such as Target and Lowe's lifted investor sentiment.US Marketsread more
President Trump insists the economy is healthy and says the only thing holding U.S. growth back is the Federal Reserve.Marketsread more
Trading volumes this week are well below their recent averages and that means this comeback may be suspect.Marketsread more
The rule could defy a 2015 Flores Settlement Agreement court order that says families cannot be held in detention for more than 20 days.Politicsread more
A key indicator for the commercial real estate market is showing signs of weakness, and uncertainty in the economy over the trade war and interest rates may be to blame.Real Estateread more
Bank of America CEO Brian Moynihan is not worried about an economic slowdown, saying the U.S. consumer is still in a strong place.Banksread more
In a second-round of tweets aimed at the U.S. central bank, the president asked, "WHERE IS THE FEDERAL RESERVE?"Marketsread more
Novavax shares rose more than 4 percent at Tuesday's market open after the bio-pharmaceutical firm said its Ebola vaccine showed promising results in an early-stage trial.
Novavax said the Ebola GP Vaccine was well tolerated in the trial involving 230 healthy adults, and that it elicited very high Ebola antibody responses at all dose levels, the company said on Tuesday.
Read MoreEbola vaccine trials in Liberia
Several pharmaceutical stocks surged last year after the Center for Disease Control and Prevention confirmed the first U.S. case of the deadly disease. Tekmira Pharmaceuticals, which was working on a treatment, saw a more than 20 percent jump in after-hours trade following the announcement.
Despite early positive headlines, Tekmira said Monday that it would suspend its Ebola research, following an acknowledgement that its treatment would likely fail in a clinical trial.
Gaithersburg, Maryland-based Novavax's shares have risen more than 50 percent since Feb. 12, when the company said it began testing its Ebola vaccine in humans.
—The Associated Press and Reuters contributed to this report.